Remove Development Remove Licensing Remove Pharmaceuticals
article thumbnail

Asian Healthcare Group Develops Vital High-Tech Platform, Beating Back COVID-19

CIO Business Intelligence

Developed by Zuellig Pharma, eZRx is ASEAN’s largest B2B eCommerce platform for the healthcare industry – offering a smarter and more convenient way to buy and sell healthcare products online, anywhere and anytime, versus reps visiting clients face-to-face. And it happened to launch when the world needed it most.

article thumbnail

Navigating the cloud maze: A 5-phase approach to optimizing cloud strategies

CIO Business Intelligence

WALK FASTER: Develop cloud adoption planning and migration roadmap With the CoE and EA teams working in tandem, its time to engage the business stakeholders/product owners and develop the plan and roadmap. The effectiveness of the cloud CoE comes into play in this phase.

Cloud 245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck Life Sciences banks on RPA to streamline regulatory compliance

CIO Business Intelligence

The pharmaceutical industry is a highly regulated one, especially for multinationals doing business across the globe. Merck Life Sciences, a leading chemical and pharmaceutical company, with 60,000 employees working across 66 countries, was one of them. In the development control room, there are 25 users with different roles.

Banking 245
article thumbnail

What is NLP? Natural language processing explained

CIO Business Intelligence

Eli Lilly overcomes translation bottleneck: With global teams working in a variety of languages, the pharmaceutical firm developed Lilly Translate, a home-grown NLP solution, to help translate everything from internal training materials and formal, technical communications to regulatory agencies. NLTK is offered under the Apache 2.0

Course 355
article thumbnail

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

GeekWire

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax Photo). Net losses were $5.3 million in 2019 and $18.9

article thumbnail

Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology

GeekWire

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Simpson was formerly the CEO of PvP Biologics, another IPD spinout, which he oversaw from the company’s launch through its sale to the pharmaceutical company Takeda. Icosavax Photo).

article thumbnail

Seattle Children’s spins out BrainChild Bio, a startup developing therapies for incurable brain cancers

GeekWire

The startup has an exclusive license to use novel CAR T-cell technology developed by Jensen and his team. BrainChild Bio will take with it about 18 people research and development employees from Seattle Children’s Therapeutics, which will continue working on childhood leukemia, lupus and other diseases.